18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

18 F-fluoride Positron emission tomography (PET) is able to demonstrate and quantify the metabolic activity locally in the skeleton (1). This technique should, therefore, also be able to demonstrate a dramatic decrease in the metabolic activity in localized monostotic Paget's disease lesions after therapy. In this condition, indeed, the usual biological markers may be unhelpful to assess the efficacy of therapy, because they are usually comprised in the normal range for single pagetic localizations, even before therapy (2). The main purpose of this trial is to assess the early and long term response of pagetic bone to bisphosphonate therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Université Catholique de Louvain
• Collaborators: FNRS (Belgium); Fonds National de la Recherche Scientifique
• Treatments: Diphosphonates; Fluorides

Criteria

Inclusion Criteria:

• Patients with a monostotic form of PDB (as attested by plain X-rays and 99mTc MDP bone scintigraphy)

• Bone pain linked to Paget's disease itself

Exclusion Criteria:

• Bisphosphonate therapy within the year prior to the study